X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

First Patient Adopting TAC-001 Has Been Announced By Tallac

Content Team by Content Team
1st August 2022
in Clinical Trials, News
First Patient Adopting TAC-001 Has Been Announced By Tallac

In a phase 1/2 clinical trial for patients with locally advanced or metastatic solid tumours, Tallac Therapeutics has reported that the first patient has received treatment with TAC-001. TAC-001 is the first clinical candidate from the company’s innovative toll-like receptor agonist antibody conjugate (TRAAC) system to enter the clinic.

According to Hong Wan, chief executive officer of Tallac, the beginning of the first-in-human study for their main therapeutic candidate is a critical milestone for Tallac as they continue to expand their differentiated portfolio of immunotherapy medicines generated from their TRAAC technology.

They are advancing extra resources in their pipeline as this study progresses, and they intend to submit an investigational new medication application at the start of next year for the phase 1 study. This therapeutic candidate targets dendritic cells via SIRP-alpha receptors and is a systemically administered toll-like receptor 9 agonist, Wan continued.

For patients with specific advanced or metastatic solid tumours, the phase 1/2 experiment known as INCLINE-101 is an open-label, multi-center, dose progression and extension study of TAC-001. Its purpose is to assess the intravenously administered TAC-001’s safety, pharmacokinetics, and preliminary anti-tumor activity.

According to Candy Bermingham, vice president of clinical science at Tallac, TAC-001 is distinctive in that it combines B cells and TLR9 activation to generate adaptive and innate immune anti-tumor immune function and has in preclinical trials shown significant single-agent effectiveness. They look forward to gaining a better understanding of the clinical efficacy of TAC-001 in progressing solid tumours and the possibility of such a chemical to address the significant unmet therapeutic requirements that still exist in a variety of cancer types.

Immunotherapies known as toll-like receptor 9 (TLR9) agonists produce combined innate and adaptive immune responses, which may result in more potent and long-lasting anti-cancer immunity to assist in combating resistance to conventional oncology treatments.

When given intratumorally, TLR9 agonists have shown clinical activity in melanoma patients. B cells, which mostly associate with tertiary lymphoid structures and express TLR9 and play a crucial role in the immune system, constitute a significant part of the tertiary lymphoid structure (TLS). In many different types of solid tumours, the presence of B cells and TLS is a favourable prognostic feature and predicts the therapeutic response to checkpoint inhibitors.

Previous Post

Arcutis Receives FDA Nod For Their Zoryve Psoriasis Cream

Next Post

Data For Treatment of Schizophrenia Disclosed By Cyclerion

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post
Data For Treatment of Schizophrenia Disclosed By Cyclerion

Data For Treatment of Schizophrenia Disclosed By Cyclerion

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In